Anika Therapeutics (ANIK) Tops Q4 EPS by 28c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.81 --0%
Revenue Growth %: +7.0%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +7.0%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.05, $0.28 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $43 million versus the consensus estimate of $41.4 million.
GUIDANCE:
Anika Therapeutics sees FY 2024 revenue of $168-173 million, versus the consensus of $179.4 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HP Inc. projects mid-single-digit PC market decline in 2027
- KeyBanc Reiterates Overweight Rating on Brinker Int'l (EAT)
- CLSA Reiterates Outperform (2) Rating on CSL Ltd. (CSL:AU) (CMXHF)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
